Google AI
NewsPronto

 

PR Newswire

AACR OVARIAN CANCER CONFERENCE PRESENTATION

  • Written by: PR Newswire Asia - News Pronto RSS

HIGHLIGHTS

  • Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA. 
  • Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer
  • Data from these studies support...

Read more: AACR OVARIAN CANCER CONFERENCE PRESENTATION